{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:40:20Z","timestamp":1788316820388,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["225790\/Z\/22\/Z"],"award-info":[{"award-number":["225790\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.atherosclerosis.2026.120723","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:44:59Z","timestamp":1774395899000},"page":"120723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Genetically proxied IL-6 signaling inhibition, lipoprotein(a) levels, and atherosclerotic disease risk"],"prefix":"10.1016","volume":"415","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6924-0641","authenticated-orcid":false,"given":"Iyas","family":"Daghlas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios K.","family":"Georgakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen O.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit J.","family":"Arsenault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipender","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.atherosclerosis.2026.120723_bib1","first-page":"1728","article-title":"Interleukin-6 signaling and Anti-Interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res Lippincott Williams and Wilkins"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2026.120723_bib2","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"10289","key":"10.1016\/j.atherosclerosis.2026.120723_bib3","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120723_bib4","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120723_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.athplu.2023.09.001","article-title":"Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: is there an association?","volume":"54","author":"Makris","year":"2023","journal-title":"Atherosclerosis Plus"},{"key":"10.1016\/j.atherosclerosis.2026.120723_bib6","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1017\/pcm.2023.5","article-title":"Mendelian randomization as a tool to inform drug development using human genetics","volume":"1","author":"Daghlas","year":"2023","journal-title":"Cambridge prisms Precision medicine"},{"key":"10.1016\/j.atherosclerosis.2026.120723_bib7","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2026.120723_bib8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120723_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.119.002872","article-title":"Interleukin-6 signaling effects on ischemic stroke and other cardiovascular outcomes: a mendelian randomization Study","volume":"13","author":"Georgakis","year":"2020","journal-title":"Circ Genom Precis Med"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120723_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12916-022-02446-6","article-title":"Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups","volume":"20","author":"Georgakis","year":"2022","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.120723_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003444","article-title":"Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases","volume":"9","author":"Ferreira","year":"2013","journal-title":"PLoS Genet"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2026.120723_bib12","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s44161-025-00700-7","article-title":"IL6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic risk","volume":"4","author":"Zhang","year":"2025","journal-title":"Nat Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120723_bib13","article-title":"Genetic analysis of over half a million people characterises C-reactive protein loci","volume":"13","author":"Said","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.atherosclerosis.2026.120723_bib14","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"7","author":"Hemani","year":"2018","journal-title":"eLife"},{"issue":"26","key":"10.1016\/j.atherosclerosis.2026.120723_bib15","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120723_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old Age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120723_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.045423","article-title":"Genetically predicted levels of Lipoprotein(a) and risk of cerebrovascular disease","volume":"15","author":"Daghlas","year":"2026","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120723_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.120723_bib19","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.cell.2016.10.042","article-title":"The allelic landscape of human blood cell trait variation and links to common complex disease","volume":"167","author":"Astle","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2026.120723_bib20","doi-asserted-by":"crossref","unstructured":"Omarov M, Zhang L, Jorshery SD, et al. Deep learning-based detection of carotid plaques informs cardiovascular risk prediction and reveals genetic drivers of atherosclerosis. medRxiv. Published online October 18, 2024. doi:10.1101\/2024.10.17.24315675.","DOI":"10.1101\/2024.10.17.24315675"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2026.120723_bib21","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41588-022-01233-6","article-title":"Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants","volume":"54","author":"Aragam","year":"2022","journal-title":"Nat Genet"},{"issue":"7934","key":"10.1016\/j.atherosclerosis.2026.120723_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-022-05165-3","article-title":"Stroke genetics informs drug discovery and risk prediction across ancestries","volume":"611","author":"Mishra","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120723_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120723_bib24","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ije\/dyr036","article-title":"Avoiding bias from weak instruments in mendelian randomization studies","volume":"40","author":"Burgess","year":"2011","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.atherosclerosis.2026.120723_bib25","doi-asserted-by":"crossref","unstructured":"Carter AR, Gill D, Davies NM, et al. Understanding the consequences of education inequality on cardiovascular disease: mendelian randomisation study. BMJ. Published online May 22, 2019:l1855. doi:10.1136\/bmj.l1855.","DOI":"10.1136\/bmj.l1855"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.120723_bib26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2026.120723_bib27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2026.120723_bib28","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","article-title":"Large-scale integration of the plasma proteome with genetics and disease","volume":"53","author":"Ferkingstad","year":"2021","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120723_bib29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/ng.3190","article-title":"Efficient Bayesian mixed-model analysis increases association power in large cohorts","volume":"47","author":"Loh","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2026.120723_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.818574","article-title":"Calculating Polygenic Risk Scores (PRS) in UK biobank: a practical guide for epidemiologists","volume":"13","author":"Collister","year":"2022","journal-title":"Front Genet"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2026.120723_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014328","article-title":"Effects of inhibition of Interleukin-6 signalling on insulin sensitivity and lipoprotein (A) levels in human subjects with rheumatoid diseases","volume":"5","author":"Schultz","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.120723_bib32","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"M\u00fcller","year":"2015","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2026.120723_bib33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/gepi.21998","article-title":"Bias due to participant overlap in two-sample Mendelian randomization","volume":"40","author":"Burgess","year":"2016","journal-title":"Genet Epidemiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:44:08Z","timestamp":1779252248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026000894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":33,"alternative-id":["S0021915026000894"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120723","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetically proxied IL-6 signaling inhibition, lipoprotein(a) levels, and atherosclerotic disease risk","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120723"}}